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Summary
Objective: Interleukin-1b (IL-1b) plays a key role in the pathogenesis of chronic joint diseases, including osteoarthritis (OA), and drives a cas-
cade of inﬂammatory and destructive responses within the synovial joint. Animal models of arthritis support the role of IL-1b in joint pathology,
however, the molecular changes downstream of IL-1b are poorly understood in vivo. This study aimed to evaluate the intra-articular (i.a.) in-
jection of IL-1b in the rat joint as an acute model of joint disease and associate gene and mediator expression with clinical endpoints and
pathological changes.
Methods: The effects of i.a. administration of a pathologically relevant dose of IL-1b on joint swelling, mechanical hyperalgesia, histopathol-
ogy, gene expression and biochemical changes were measured from 2 to 24 h.
Results: IL-1b-induced joint swelling and mechanical hyperalgesia. Gene expression analysis of joint tissue and biochemical analysis of joint
lavage ﬂuid identiﬁed pro-inﬂammatory and destructive mediators induced by IL-1b. Histopathology of joint tissues showed evidence of syno-
vitis and connective tissue inﬂammation, but not cartilage destruction. However, biochemical analysis of glucosaminoglycan levels in joint
lavage ﬂuids indicated cartilage breakdown and might be a sensitive marker of cartilage pathology.
Conclusions: Intra-articular injection of IL-1b is a reproducible acute model of joint pathology that is potentially useful to evaluate IL-1 pathway
inhibitors. The correlation of molecular events with clinical and pathological changes in this model has enhanced the understanding of the role
of IL-1b in joint disease. Methods developed for gene expression analysis using multi-gene microﬂuidics cards and for biochemical analysis of
joint lavage ﬂuid might have utility for characterisation of other arthritis models and corresponding human disease.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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musculo-skeletal disease and is estimated to affect 300 mil-
lion people worldwide with an increasing prevalence1. The
clinical symptoms of OA are pain and functional disability
that can prevent normal activities of daily life and can lead
to isolation and depression2. OA is a disease of the whole
joint principally characterised by a chronic degeneration of
articular cartilage but pathological changes also include sy-
novial inﬂammation, bone remodelling, and muscle weak-
ness3. Evidence suggests that synovitis is a cause of pain
and can contribute to structural deterioration of the joint in
OA4e6. Current therapies for OA are analgesics and anti-
inﬂammatory drugs that reduce the symptoms of OA but
there remains a high unmet medical need for treatments
that address the underlying causes of OA7.
The cytokine interleukin-1b (IL-1b) drives a wide range of
pro-inﬂammatory and destructive responses in a number of
cell types in the synovial joint and plays a key role in the*Address correspondence and reprint requests to: Ian Scott,
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1509-645557; E-mail: Ian.Scott@astrazeneca.com
Received 21 July 2008; revision accepted 30 September 2008.
790progression and outcome of chronic joint diseases including
OA7e9. IL-1 signalling has been suggested as an attractive
therapeutic target for reducing symptomatic and structural
changes in OA9,10. A limited number of agents that target
IL-1 have been evaluated in OA clinical trials and intra-
articular (i.a.) injection of IL-1 receptor antagonist (Anakinra;
Kineret, Amgen) has shown a signiﬁcant beneﬁt in reducing
pain and synovitis in OA patients11e13.
Animal models of arthritis, whilst not fully representative
of human joint diseases, can be used to increase under-
standing of the mechanisms underlying joint pathology
and for the evaluation of potential therapeutic agents14.
Proﬁling the pro-inﬂammatory and destructive mediators
involved in animal models of arthritis can provide insight
into the relationship with human joint disease and poten-
tially help identify the appropriate model to evaluate spe-
ciﬁc therapeutic agents15e18. Although IL-1b has been
demonstrated to have a pro-inﬂammatory and pro-
catabolic role in animal models of arthritis, the molecular
basis of pathological changes are still poorly characteri-
sed19e23. In particular, IL-1b-driven models of arthritis
have demonstrated a role of IL-1b in synovial
inﬂammation and cartilage destruction but have not sur-
veyed the pro-inﬂammatory and destructive mediators
involved24e26.
791Osteoarthritis and Cartilage Vol. 17, No. 6The objective of this study was to evaluate i.a. injection of
IL-1b in rat ankle joint as an acute model of joint destruction
and characterise pathological events relevant to human ar-
thritis including pain, synovitis and cartilage destruction.
A particular aim was to explore the cascade of molecular
events induced by IL-1b in vivo and correlate with clinical
endpoints and histopathological changes. The identiﬁcation
of a reproducible model with short duration, when compared
to more complex models of arthritis, would be useful for ini-
tial evaluation of antagonists of the IL-1 pathway. In addi-
tion, this acute model might be appropriate to develop
gene expression and biochemical methodologies with utility
in other models of arthritis.Materials and methodsANIMALSFemale Lewis rats (175e200 g, Charles River, UK) were group housed (5
per cage), allowed food and water ad libitum, and acclimatised for a minimum
of 1 week prior to sensitisation. Animals were housed in light/dark cycles of
12 h. All in vivo work in rats was subject to internal ethical review and con-
ducted strictly in accordance with Home Ofﬁce requirements under the Ani-
mals (Scientiﬁc Procedures) Act 1986.INTRA-ARTICULAR INJECTION OF IL-1b4.80
AThe rats were anaesthetised with isoﬂurane prior to an i.a. injection of 10 ng
or 100 ng of rat IL-1b (R&D Systems) in 20 ml of phosphate buffer saline (PBS,
Dulbecco A) into the ankle joint space. Contra-lateral ankle joints injected with
20 ml of PBS served as vehicle controls (ﬁve animals per treatment group). An-
kle joint diameters were measured using vernier callipers and mechanical hy-
peralgesia measured using von Frey ﬁlaments. Animals were terminated 2, 4,
8 and 24 h after i.a. injection. In vivo procedures and the subsequentmeasure-
ment of clinical parameter were repeated in three independent experiments.4.60
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(Ankle joints were ﬁxed in 10% neutral buffered formalin, decalciﬁed and
processed to wax according to standard protocols. Tibialetalus joint sections
of 4 mm thickness were stained with hematoxylin and eosin (H&E). Sections
were examined microscopically and a blind assessment of pathology was
made using a subjective semi-quantitative scoring system. Individual sec-
tions were graded as follows: grade 0¼ no lesion, grade 1¼minimal, grade
2¼ slight, grade 3¼moderate, grade 4¼marked/severe. Additional joint
sections were stained with toluidine blue to further assess potential changes
to articular cartilage. Histological analysis was performed on samples from
two independent experiments.0 5 10 15 20 25
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An incision was made between the calcaneum and talus bones and the
joint lavaged with 100 ml PBS containing 0.05 mM EDTA at 2, 4 and 24 h
post-i.a. injection. Biochemical analyses of joint lavage ﬂuid were performed
on samples from three independent experiments.5.40
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nosorbent assay (ELISA) using manufacturer’s instructions (R&D Systems).5.70
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nLavage ﬂuids were digested in 500 mg/ml papain solution at pH 6.5 at
60 C for 18 h. GAG concentrations were measured using a dimethyl meth-
ylene blue (DMMB) assay using a chondroitin sulphate standard curve27.0 5 10 15 20 25
Time post injection (hours)RNA ISOLATIONFig. 1. Ankle swelling (mm) (A) and mechanical hyperalgesia (von
Frey Threshold, log g) (B) induced by i.a. injection of 10 ng IL-1b
(red lines) and saline vehicle control (blue). *Statistical signiﬁcance
in paired t-test (P< 0.05).Whole ankle joints, after removal of skin and muscle tissues, were snap fro-
zen in liquid nitrogen. RNAwas isolated from 250 to 500 mg tissue using TRIzol
(Invitrogen) and RNeasy Cleanup (Qiagen), with complete on column genomic
DNA digestion (RNase-free Dnase, Qiagen), according to manufacturer’sinstructions. RNA integrity was conﬁrmed using RNA6000 nano-assay (Agilent
Technologies) and RNA concentration quantiﬁed spectrophotometrically.GENE EXPRESSIONcDNA was prepared from 2 mg of RNA samples using 250 mg/ml random
primers and Superscript III reverse transcriptase (Invitrogen) according to
manufacturer’s instructions. The concentrations of cDNA samples were
quantiﬁed using Quant-iT RiboGreen assay (Molecular Probes). Relative
quantiﬁcation of gene expression using polymerase chain reaction (PCR)
for 47 selected genes was performed with HotGoldStar DNA polymerase
mix (Eurogenics) using 5 mg/ml of cDNA and custom designed 384-well Taq-
Man Microﬂuidics cards (Applied Biosystems) on an ABI system 7900HT ma-
chine. Relative gene expression was normalised by comparison to 18S RNA
expression levels. RNA isolation and gene expression analysis was per-
formed on samples from three independent experiments.DATA ANALYSISDifference in mean values from different treatment groups were analysed
by paired and unpaired t-tests using Instat 3.0 software. Statistical signiﬁ-
cance is expressed as *P< 0.05. All ﬁgures are taken from individual repre-
sentative studies.
ResultsEFFECT OF IL-1b ON RAT ANKLE SWELLING AND MECHANICAL
HYPERALGESIAAnalysis of the i.a. levels of IL-1b in an animal model of
arthritis allowed a pathologically relevant dose to be chosen
for initial experiments to investigate the effect of i.a. IL-1b on
joint pathology. IL-1b, 10 ng i.a., was calculated to generate
Table I
Summary of the relative gene expression of 47 selected genes in whole joint tissue 4 h after i.a. IL-1b or vehicle control. Fold increase and
decrease refer to comparison of relative expression level in IL-1b treated and vehicle control treated joint tissue. *Statistical significance in
paired t-test (P< 0.05). Threshold cycle (Ct) for gene of interest e Ct for 18S RNA (DCt), not detected (ND)
Gene symbol Encoded protein DCt vehicle DCt
IL-1b
Fold
increase
Fold
decrease
P-value
ADAMTS5 A disintegrin-like and metalloprotease, Aggrecanase-2 15.0 13.1 3.3 0.042*
AGC1 Aggrecan 11.4 11.0 1.4 0.589
Alp1 Alkaline phosphatase 13.3 6.2 22356.0 0.308
B2M Beta-2 microglobulin 8.6 7.6 1.9 0.209
BMP Bone morphogenetic protein 2 18.6 23.7 1.3 0.563
CACNA2D2 Voltage-dependent calcium channel alpha 2 delta subunit 2 ND ND
CASP3 Caspase-3 15.3 16.1 1.7 0.609
CNR1 Cannabinoid receptor 1 ND ND
CNR2 Cannabinoid receptor 2 ND ND
COL1A1 Procollagen chain, type I, alpha 1 7.2 6.8 1.4 0.449
COL2A1 Procollagen chain, type II, alpha 1 16.0 15.7 1.5 0.661
COL3A1 Procollagen chain, type III, alpha 1 8.7 8.7 1.1 0.682
COMP Cartilage oligomeric matrix protein 10.6 18.5 1.4 0.422
CTSK Cathepsin K 11.9 11.7 1.1 0.564
FGF2 Fibroblast growth factor 2 17.1 17.4 1.1 0.993
FN1 Fibronectin 7.1 6.5 1.5 0.398
HEXA Hexosaminidase A 16.6 16.6 1.1 0.819
HPRT Hypoxanthine guanine phosphoribosyl transferase 10.2 12.5 7.2 0.520
HYAL1 Hyaluronidase 1 15.1 15.1 1.3 0.777
HYAL2 Hyaluronidase 2 17.4 16.5 1.7 0.462
IGF1 Insulin-like growth factor 1 12.5 11.8 1.7 0.543
IGFBP-4 Insulin-like growth factor binding protein-4 13.3 12.5 1.8 0.036*
IL-18 Interleukin 18 14.3 13.7 2.1 0.423
IL-1a Interleukin 1 alpha 13.3 16.0 7.8 0.079
IL-1b Interleukin 1 beta 16.6 13.0 13.6 0.006*
IL-1r1 Interleukin 1 receptor, type I 13.6 12.3 2.6 0.026*
IL-1r2 Interleukin 1 receptor, type II 16.0 14.5 2.4 0.069
IL-1rN Interleukin 1 receptor antagonist 15.6 9.5 1033.0 0.150
IL-6 Interleukin-6 16.4 11.8 21.8 0.006*
MMP3 Matrix metalloproteinase 3 14.5 12.2 12.0 0.300
MMP7 Matrix metalloproteinase 7 ND 36.0
NFkB1 Nuclear factor of kappa light chain gene enhancer 14.7 13.0 3.1 0.029*
NOS2 Nitric oxide synthase 2, inducible 17.7 10.2 120.0 0.003*
P2RX7 Purinergic receptor P2X, ligand-gated ion channel, 7 15.3 15.8 1.3 0.856
PDK4 Pyruvate dehydrogenase kinase, isoenzyme 4 22.1 15.8 3.1 0.003*
PLAU Plasminogen activator, urokinase 14.9 14.0 1.8 0.169
PTGS2 Prostaglandin synthase 2 17.4 14.2 7.6 0.022*
RUNX2 Runt related transcription factor 2 17.7 16.9 1.8 0.438
S100A4 S100 calcium-binding protein A4 11.0 9.9 2.2 0.101
SLC20A1 Solute carrier family 20 phosphate transporter, member 1 16.2 14.6 3.1 0.092
SLC7A2 Solute carrier family 7, Cationic amino acid transporter,
yþ system, member 2
13.7 11.8 3.1 0.089
TGFB1 Transforming growth factor, beta 1 13.1 12.3 1.8 0.145
TIMP-1 Tissue inhibitor of metalloproteinase-1 12.8 10.3 5.1 0.0001*
TIMP-3 Tissue inhibitor of metalloproteinase-3 10.6 9.5 1.9 0.01*
TNF Tumour necrosis factor-alpha 28.9 17.6 9.0 0.001*
TRPV4 Transient receptor potential cation channel, subfamily V,
member 4
14.7 13.9 1.5 0.098
VCAM-1 Vascular cell adhesion molecule-1 14.9 13.6 1.9 0.034*
VEGFA Vascular endothelial growth factor 14.5 13.6 1.9 0.015*
792 I. Scott et al.: Acute IL-1b model of joint pathologya concentration of IL-1b in the joint equivalent to peak con-
centrations measured in ankle joint lavage ﬂuid during rat
streptococcal cell wall (SCW) model of arthritis16. At this
dose, IL-1b induced signiﬁcant ankle joint swelling com-
pared to vehicle controls 4 and 24 h after i.a. injection
[Fig. 1(a)]. IL-1b also induced a signiﬁcant increase in me-
chanical hyperalgesia compared to vehicle controls at 4 h
but this had declined by 24 h [Fig. 1(b)].EFFECT OF IL-1b ON GENE EXPRESSION IN RAT
ANKLE JOINTSQuantitative gene expression of rat ankle joint tissue,
using TaqMan-PCR microﬂuidics, was used to explorethe molecular basis for IL-1b-induced joint pathology.
The expression of 47 selected genes, encoding pro-in-
ﬂammatory and pro-degradative mediators, regulatory pro-
teins, and joint extracellular matrix components was
surveyed 4 h after a 10 ng dose of i.a. IL-1b or vehicle
control to correlate with the peak of joint swelling and me-
chanical hyperalgesia. Signiﬁcantly increased expression
of genes encoding the pro-inﬂammatory and pro-degrada-
tive mediators IL-6, IL-1b, prostaglandin synthase 2
(PTGS2), inducible nitric oxide synthase 2 (NOS2), tu-
mour necrosis factor-a (TNFa), a distintegrin-like and met-
alloprotease with thrombospondin motif-5 (ADAMTS5 or
Aggrecanase-2) and nuclear factor kappa light chain
(NFkb1) were identiﬁed (Table I). IL-1b also signiﬁcantly
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Fig. 2. A. Comparison of relative gene expression for IL-6, NOS2, PTGS2 and IL-1b 4 h after i.a. injection of 10 ng IL-1b or vehicle control.
B. Concentration of IL-6 in joint lavage ﬂuid 2, 4 and 24 h after i.a. injection of 10 ng IL-1b or vehicle control. *Statistical signiﬁcance in paired
t-test (P< 0.05).
793Osteoarthritis and Cartilage Vol. 17, No. 6
Table II
Summary of incidence and severity of histopathological changes in
rat tibialetalus joint 2, 4 and 24 h after i.a. IL-1b (left ankle) or vehi-
cle control (right ankle). Histopathology changes were scored blind
using semi-quantitative/subjective grading system (grade 0¼ no
lesion, grade 1¼minimal, grade 2¼ slight, grade 3¼moderate,
grade 4¼marked/severe)
Treatment group IL-1b Vehicle control
Time point (h) 2 4 24 2 4 24
No. of joints examined 5 5 5 5 5 5
Leukocyte margination/diapadesis
Grade 0 0 0 1 4 4 5
Grade 1 1 0 3 1 1 0
Grade 2 2 3 1 0 0 0
Grade 3 2 2 0 0 0 0
Synovitis
Grade 0 2 0 0 5 5 5
Grade 1 2 0 0 0 0 0
Grade 2 1 5 2 0 0 0
Grade 3 0 0 2 0 0 0
Grade 4 0 0 1 0 0 0
Synovial hypertrophy
Grade 0 5 2 0 5 5 5
Grade 1 0 3 3 0 0 0
Grade 2 0 0 2 0 0 0
Cellular debris in articular space
Grade 0 4 1 0 4 4 5
Grade 1 1 2 0 1 1 0
Grade 2 0 1 2 0 0 0
Grade 3 0 1 2 0 0 0
Grade 4 0 0 1 0 0 0
Blood in articular space
Grade 0 3 4 4 3 4 5
Grade 1 2 1 0 1 1 0
Grade 2 0 0 0 1 0 0
Grade 3 0 0 1 0 0 0
Connective tissue inﬂammation
Grade 0 0 0 0 4 3 3
Grade 1 3 4 1 1 2 2
Grade 2 2 1 4 0 0 0
Connective tissue necrosis
Grade 0 2 3 1 4 5 5
Grade 1 3 2 3 1 0 0
Grade 2 0 0 1 0 0 0
Haemorrhage in connective tissue
Grade 0 3 3 4 3 2 5
Grade 1 1 0 1 2 1 0
Grade 2 1 2 0 0 2 0
794 I. Scott et al.: Acute IL-1b model of joint pathologyincreased expression of genes encoding insulin-like
growth factor binding protein-4 (IGFBP-4), IL-1 receptor
type I (IL-1R1), tissue inhibitor of metalloproteinase-1
(TIMP-1), tissue inhibitor of metalloproteinase-4 (TIMP-
4), vascular cell adhesion molecule-1 (VCAM-1), and vas-
cular endothelial growth factor (VEGF).EFFECT OF IL-1b ON PRO-INFLAMMATORY MEDIATORS IN
RAT ANKLE JOINTSTo conﬁrm changes in expression of pro-inﬂammatory
mediators further independent experiments were performed
using a 10 ng dose of IL-1b or vehicle control into rat ankle
joints. Signiﬁcant induction of expression of genes encoding
IL-6, NOS2, PTGS2 and IL-1b were conﬁrmed [Fig. 2(a)].
To determine if changes in gene expression lead to corre-
sponding changes in levels of pro-inﬂammatory mediatorsIL-6, PGE2 and nitric oxide (NO) were measured in joint la-
vage ﬂuids after treatment with IL-1b or vehicle control. IL-6
protein levels in joint lavage ﬂuid were signiﬁcantly induced
4 h after treatment, in agreement with increased IL-6 gene
expression, and returned to levels in vehicle controls at
24 h [Fig. 2(b)]. A 10 ng dose of IL-1b did not signiﬁcantly
increase levels of NO in lavage ﬂuid 2e24 h after treatment.
However a 100 ng dose of IL-1b induced mean NO levels
5.4-fold greater than vehicle control at 8 h (P< 0.05, data
not shown) consistent with increases in NOS2 gene expres-
sion. Levels of PGE2 in joint lavage ﬂuids were below de-
tection levels of the assay and could not be compared
with PTGS2 gene expression.EFFECT OF IL-1b ON HISTOPATHOLOGY OF RAT
ANKLE JOINTSAs a direct consequence ofmechanical trauma associated
with the insertion of the injection needle and/or inherent vehi-
cle irritancy i.a. injection of 20 ml of sterile PBS vehicle alone
gave rise to minor histopathological changes at 2, 4 and 24 h
post-injection (Table II). The changes recorded at 2 and 4 h
post-injection included blood and cellular debris in the articu-
lar space, leukocyte margination/diapedesis in vasculature
of adjacent connective tissue, and haemorrhage, inﬂamma-
tion and necrosis of connective tissue (some of which was
clearly associated with needle track injury). Connective tis-
sue inﬂammation was also noted in joints from two rats at
24 h post-injection. All these changes were minimal (grade
1), with the exception of grade 2 (slight) i.a. haemorrhage
in one joint 2 h post-injection.
IL-1b, 10 ng i.a., exacerbated the histopathology changes
seen with PBS vehicle alone (Table II). Leukocyte margin-
ation and diapedesis associated with synovial blood vessels
were most noticeable at 2 and 4 h [Fig. 3(a,b)], with evidence
of resolution at 24 h post-injection. In contrast, synovitis, sy-
novial hypertrophy and adjacent synovial connective tissue
inﬂammation all increased in incidence and severity with
time, the most severe changes being evident at 24 h post-in-
jection. This also applied to the presence of cellular debris in
the articular space [Fig. 3(c,d)]. The other changes recorded
are equivocal, being similar in incidence and severity to the
changes seen with vehicle alone. Examination of toludine
blue-stained joint sections provided no overt evidence of ar-
ticular IL-1b-related cartilage degradation at any of the three
time points (2, 4 and 24 h post-injection) [Fig. 3(e,f)].BIOCHEMICAL ANALYSIS OF THE EFFECT OF IL-1b ON
CARTILAGE PROTEOGLYCAN DEGRADATION IN
RAT ANKLE JOINTSTo further investigate the effect of IL-1b on articular carti-
lage pathology, the concentration of GAG in joint lavage
ﬂuid was determined after i.a. injection of IL-1b or vehicle
control. A 10 ng dose of IL-1b showed a trend to increase
GAG concentration in joint lavage ﬂuid compared to vehicle
controls after 4 and 24 h although this was not statistically
signiﬁcant [Fig. 4(a)]. In a further study, a 100 ng dose of
IL-1b induced a signiﬁcant increase in GAG concentration
in lavage ﬂuid at 4 and 8 h [Fig. 4(b)].Discussion
To our knowledge this is the ﬁrst attempt to assess gene
and functional mediator expression alongside the clinical
and histopathological effects of i.a. injection of IL-1b in
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Fig. 3. Representative tissue sections illustrating the effect of IL-1b on histopathology of rat tibialetalus joints; (A) 2 h after i.a. injection of IL-1b
leukocytes, predominantly neutrophils, are lining the vessel against the endothelium (margination). The inserted image shows evidence of
inﬂammatory cells passing through a vessel wall (diapadesis, arrow); (B) 2 h after injection of PBS margination and diapadesis were less ev-
ident compared to injection of IL-1b. (C) and (D) Images illustrate inﬂammatory changes in a representative tibialetalus joint 4 h after injection
of IL-1b; (D) shows a high power image of the boxed region in (C). Synovitis (synovial inﬂammation, SI) and inﬂammatory cell debris (CD) in
the i.a. space (IA) are apparent. Inﬂammatory changes and their sequele were less apparent at 2 h and were more pronounced at 24 h after
injection of IL-1b (images not shown). Tibia (Ti), Talus (Ta). (E) and (F) Images show a representative tibialetalus joint 24 h after injection of IL-
1b stained with toludine blue. Panel F shows a high power image of the boxed region in (E). There is no overt histological evidence of cartilage
degradation/damage. Calcaneum (Cal), articular cartilage (Car).
795Osteoarthritis and Cartilage Vol. 17, No. 6a single study. We have shown that i.a. injection of IL-1b can
induce a cascade of pro-inﬂammatory and pro-degradative
mediators in the rat ankle joint that potentially lead to the in-
duction of an acute hyperalgesia, synovial inﬂammation and
cartilage breakdown. The correlation of the pathological ef-
fects of IL-1bwith changes in pro-inﬂammatory and pro-deg-
radative mediator expression provide a new insight into the
role of the IL-1 pathway in joint disease.
This study demonstrated that a single dose of IL-1b, equiv-
alent to levels measured in the SCWmodel of chronic arthri-
tis16, was sufﬁcient to drive an acute joint pathology.
Although the doses of IL-1 identiﬁed in this inﬂammatory
model potentially exceed those found in an OA joint, this
study, by utilising physiologically relevant doses of IL-1, con-
trasts with previous studies in which the relevance of thechosen IL-1b doses were unclear24e26,28e30. Intra-articular
injection of IL-1b into the rat ankle joint induced an acute
swelling of the joint with similarities to a previous study in
rats24. IL-1b also produced a sequence of clinical changes
including early evidence of acute mechanical hyperalgesia
which is previously unreported. IL-1b induced a time course
of histopathological changes including early evidence of leu-
kocyte margination and diapadesis in synovial blood vessels
leading to synovial inﬂammation (with synovial hypertrophy)
and the accumulation of cellular debris in the articular space.
These effects extend previous reports that i.a. IL-1b can in-
duce a cellular inﬁltrate in the synovial lining and ﬂuid, and sy-
novitis26,29. There was no histological evidence that IL-1b
induced acute cartilage destruction, however, biochemical
analysis of joint lavage ﬂuid revealed that IL-1b increased
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Fig. 4. (A) Concentration of GAG in joint lavage ﬂuid 2, 4 and 24 h
after i.a. injection of 10 ng IL-1b (shown in red) or saline vehicle
control (blue). (B) Concentration of GAG in joint lavage ﬂuid 4
and 8 h after i.a. injection of 10 ng or 100 g IL-1b (red) or vehicle
control (blue). *Statistical signiﬁcance in paired t-test (P< 0.05).
796 I. Scott et al.: Acute IL-1b model of joint pathologythe release of GAG, a marker of cartilage breakdown27,
within 4e8 h. This conﬁrms that analysis of GAG in joint la-
vage ﬂuid might be amore sensitive method of detecting car-
tilage breakdown than histological analysis26. In addition, the
DMMB assay for GAG has the advantage that it can be com-
pleted in a few hours after collection of lavage ﬂuid compared
to the time required to process and section joints for micro-
scopic examination (about 6 weeks, mainly taken up by the
decalciﬁcation procedure). A single i.a. injection of IL-1b in
rat joints has been shown to induce cartilage pathology 7
days after treatment but GAG analysis of rat lavage ﬂuid
has not been reported previously24.
Delineating the molecular pathways involved in an animal
model of arthritis can provide insight into the associations
with human joint disease and could be used to identify the ap-
propriate model to evaluate therapeutic agents15,17,18. This
study is the ﬁrst to identify IL-1b-induced changes in gene ex-
pression andmediator release in the synovial joint and corre-
late these with joint inﬂammation, pain, and histopathological
changes. As IL-1b was likely to affect a number of cell types
in the joint, we analysed changes in gene expression in
whole joint tissue as used in models of arthritis for gene mi-
croarray analysis15,17,18. IL-1b induced the gene expression
of a range of pro-inﬂammatory and pro-degradative media-
tors, including IL-6, PTGS2, NOS2, TNFa, NFkB1ADAMTS5and IL-1b, simultaneously with the peak of joint in-
ﬂammation and hyperalgesia. IL-1b also increased the gene
expression of IGFBP4, TIMP-1 and -4 and IL-1r1 encoding
regulators of growth factor, protease and cytokine activity
with roles in joint tissue remodelling. IL-1b increased expres-
sion of genes encoding VCAM-1 and VEGF, which have
roles in endothelial cell adhesion and function, respec-
tively31,32, and might contribute to the IL-1b-induced leuko-
cyte margination, diapedesis and cell inﬁltration observed
in this study. This study has demonstrated the utility of quan-
titative-PCR, using customised multi-gene microﬂuidic
cards, to explore gene expression changes in an experimen-
tal model of arthritis. Future work could extend gene expres-
sion analysis to include additional key degradative
mediators, including the collagenases MMP-13 and -8, and
potential pain mediators such as nerve growth factor. Al-
though microﬂuidic cards are focused on analysis of
10se100s of selected genes, compared to 1000s analysed
by global gene microarrays, they have the advantage of be-
ing able to analyse a large number of samples with high sen-
sitivity and dynamic range33. Thus microﬂuidics-based PCR
might be a useful addition to the range of tools to study both
animal models and the associated human disease.
Previous studies detailing gene expression changes in
models of arthritis did not conﬁrm that they lead to changes
in protein levels or biological activity15,17,18. In this study, we
demonstrated that IL-1b induced the accumulation of IL-6
protein and NO in joint lavage ﬂuid consistent with
increases in IL-6 and NOS2 gene expression in joint tissue.
Induction of NO levels in rat joint lavage ﬂuid was consistent
with a previous study using a 1000 ng dose of i.a. IL-1b30. In
contrast, levels of PGE2 in joint lavage ﬂuid were below de-
tectability of the assay used and could not be correlated
with increases in PTGS2 gene expression. Overall these re-
sults support the utility of gene expression analysis in ani-
mal models, particularly when limited amounts of lavage
ﬂuids, assay sensitivity, or the lack of availability of suitable
reagents restrict biochemical analysis.
In conclusion, the present study has demonstrated that
IL-1b can drive an acute joint pathology that is mediated
by a range of the pro-inﬂammatory and destructive media-
tors. The reproducibility of this acute model indicates that
it could be used for initial evaluation of the therapeutic po-
tential of novel antagonists of the IL-1 pathway before com-
mitting to complex arthritis models of increased duration
and variability. In addition, consistent responses in this
model have enabled the development of methods to char-
acterise molecular changes, alongside clinical endpoints,
which might have utility in studies of other animal models
and human disease. Future work will aim to extend the
time course of the model to further understand disease pro-
gression. Genome-wide microarray techniques will be used
to increase knowledge of molecular events downstream of
IL-1 in the synovial joint.Conﬂict of interest
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